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chronic stable angina: a randomised, placebo controlled 
crossover trial
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Summary
Background Experimental evidence suggests that xanthine oxidase inhibitors can reduce myocardial oxygen 
consumption for a particular stroke volume. If such an eﬀ ect also occurs in man, this class of inhibitors could become 
a new treatment for ischaemia in patients with angina pectoris. We ascertained whether high-dose allopurinol 
prolongs exercise capability in patients with chronic stable angina.
Methods 65 patients (aged 18–85 years) with angiographically documented coronary artery disease, a positive exercise 
tolerance test, and stable chronic angina pectoris (for at least 2 months) were recruited into a double-blind, randomised, 
placebo-controlled, crossover study in a hospital and two inﬁ rmaries in the UK. We used computer-generated 
randomisation to assign patients to allopurinol (600 mg per day) or placebo for 6 weeks before crossover. Our primary 
endpoint was the time to ST depression, and the secondary endpoints were total exercise time and time to chest pain. 
We did a completed case analysis. This study is registered as an International Standard Randomised Controlled Trial, 
number ISRCTN 82040078.
Findings In the ﬁ rst treatment period, 31 patients were allocated to allopurinol and 28 were analysed, and 34 were allocated 
to placebo and 32 were analysed. In the second period, all 60 patients were analysed. Allopurinol increased the median 
time to ST depression to 298 s (IQR 211–408) from a baseline of 232 s (182–380), and placebo increased it to 249 s 
(200–375; p=0·0002). The point estimate (absolute diﬀ erence between allopurinol and placebo) was 43 s (95% CI 31–58). 
Allopurinol increased median total exercise time to 393 s (IQR 280–519) from a baseline of 301 s (251–447), and placebo 
increased it to 307 s (232–430; p=0·0003); the point estimate was 58 s (95% CI 45–77). Allopurinol increased the time to 
chest pain from a baseline of 234 s (IQR 189–382) to 304 s (222–421), and placebo increased it to 272 s (200–380; 
p=0·001); the point estimate was 38 s (95% CI 17–55). No adverse eﬀ ects of treatment were reported.
Interpretation Allopurinol seems to be a useful, inexpensive, well tolerated, and safe anti-ischaemic drug for patients 
with angina.
Funding British Heart Foundation.
Introduction
Allopurinol has been shown to improve mechano-energetic 
uncoupling in the myocardium during heart failure,1–3 
which means that it decreases myocardial oxygen demand 
per unit of cardiac output. The mechanism probably 
involves an eﬀ ect on myocardial energetics.4,5 Whatever the 
precise mechanism, the process whereby allopurinol 
reduces myocardial oxygen consumption has so far only 
been shown in heart failure and almost exclusively in 
experimental heart failure.1–5 However, a large group of 
patients who might beneﬁ t from a drug that decreases 
oxygen consumption are those with angina pectoris, but 
there are no studies (clinical or experimental) in which this 
possibility has been investigated. We therefore set out to 
investigate whether allopurinol prolongs exercise in 
patients with chronic stable angina pectoris.
Methods
Study overview
The randomised, double-blind, placebo-controlled, 
crossover trial of allopurinol in patients with angina 
pectoris was done at Ninewells Hospital, Perth Royal 
Inﬁ rmary, and Arbroath Inﬁ rmary (all in UK). It was 
approved by the Fife, Forth Valley and Tayside Research 
Ethics Committee, and was done in accordance with the 
Declaration of Helsinki. Participants provided signed, 
written informed consent.
Study protocol
Individuals (aged 18–85 years) were recruited from 
outpatients at two Tayside Hospitals. They were eligible 
if they had angiographically documented coronary artery 
disease, a positive exercise tolerance test (ETT), and a 
history of symptoms of chronic, stable, eﬀ ort-induced 
angina for at least 2 months. All concomitant antianginal 
drugs were allowed and continued unchanged during 
the study.
Exclusion criteria were inability of participant to do 
ETT because of back or leg problems (n=24), myocardial 
infarction or acute coronary syndrome for at least 
2 months, coronary revascularisation (percutaneous or 
coronary artery bypass graft) within the previous 
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6 months, left ventricular ejection fraction of less than 
45% (n=7), estimated glomerular ﬁ ltration rate of less 
than 45 mL per min or creatinine concentration greater 
than 180 mmol/mL (n=5), substantial valvular disease 
(n=1), had gout or was already taking allopurinol, atrial 
arrhythmias or electrocardiogram (ECG) abnormalities 
interfering with ST-segment interpretation, previous 
ventricular arrhythmias on ETT (n=2), or severe hepatic 
disease or taking warfarin (n=6), azathioprine (n=1), or 
6-mercaptopurine.
After an initial history and examination, participants 
underwent an ETT according to the full Bruce protocol. 
During each ETT, a 12-lead ECG was recorded 
continuously, and printed every 30 s and at the point of 
1 mm ST depression. A second ETT was done within 
14 days. Eligible participants had to manifest ischaemia 
(ST depression ≥1 mm compared with resting ECG) on 
both visits with a between-visit diﬀ erence in time to ST 
depression of less than 15%. Otherwise, a third ETT was 
done and there had to be a diﬀ erence of less than 15% 
between the second and third tests. The last baseline 
ETT before any treatment was given was used in the 
analysis. All ETTs were supervised by AN and a research 
nurse; both were unaware of the treatment allocation.
Randomisation and masking
Eligible participants were randomly assigned to allopurinol 
or matching placebo for 6 weeks. The dose of oral 
allopurinol was 100 mg once a day during the ﬁ rst week, 
300 mg once a day in the second week, and 300 mg twice 
a day during the rest of the treatment. Participants were 
then crossed over, without any washout, to the other 
treatment for a further 6 weeks. Allopurinol 600 mg per 
day was chosen because we previously showed that it 
improved endothelial function and oxidative stress much 
more than did 300 mg per day.6 A random allocation 
sequence was computer-generated elsewhere. The 
individual who prepared the blinded numbered containers 
of drugs was not otherwise connected to the study, and the 
individuals doing the study and the patients had no access 
to the allocation sequence until the end, when ﬁ nal results 
were analysed. Allocation was done by trial staﬀ  unaware 
of what treatment A or B was. All tablets were identical in 
size, colour, and taste. Overall, masking was judged to be 
good. No stratiﬁ cation was done. Patients were allowed to 
continue with all their antianginal drugs, which remained 
unchanged throughout. At the end of each treatment, 
patients were clinically assessed and underwent a further 
ETT. Thus, the baseline ETT used in the analysis was done 
before drug or placebo was given, and no further drug-
free ETT was done between the ﬁ rst and second treatments. 
The primary endpoint was the time to ST depression, and 
the secondary endpoints were total exercise time and time 
to symptoms (chest pain). In total, there were usually four 
visits—ie, two predrug baseline visits and one visit at the 
end of every treatment. Blood was monitored at visits 1, 3, 
and 4 for full blood count, urea electrolytes, and liver 
function.
The time to ST depression was analysed by two 
independent observers (AN and DSCA) who were unaware 
of the treatments; their results were virtually identical 
(Pearson r=0·9975, 95% CI 0·997–0·998). Bland Altman 
analysis bias was –0·95 s (SD 10·7; 95% CI –22 to 20). 
Blood was taken at baseline and at the end of every 
treatment phase for measurement of concentrations of 
brain natriuretic peptide and C-reactive protein. Adverse 
events were assessed by symptom enquiry at every visit 
and by monitoring routine blood samples. Patients also 
kept diaries to record anginal episodes and their intake of 
glyceryl trinitrate.
Statistical analysis
Results were presented as mean (SD) when parametric 
tests were used, and as median (IQR) when non-
parametric tests were used. For non-parametric data, a 
Mann-Whitney U test was used. We also used the 
multilevel model as recommended by Mills and colleagues7 
for analysing crossover studies. This model was used 
speciﬁ cally to allow assessment of whether there were any 
eﬀ ects with time or any carryover eﬀ ect from one treatment 
phase to another. We also used the multilevel model of 
Mills and colleagues7 to assess treatment eﬀ ect for the 
parametric data: these results were double checked by use 
of a paired t test after the exclusion of carryover eﬀ ects.8 
Point estimates (absolute diﬀ erence in time [s] between 
allopurinol and placebo) and their 95% CIs for the three 
main treatment eﬀ ects were calculated as recommended 
by Hollander and Wolfe.9
Power calculations were based originally on an expected 
average improvement of 50 s (SD 90) in the time to ST 
depression, as from previous reports.10–15 We only needed 
34 individuals in a crossover study to have 90% power at Figure 1: Trial proﬁ le
101 participants assessed
 for eligibility
First treatment
period
Crossover
36 excluded because did not meet
 criteria for excercise tolerance
65 met criteria for excercise
 tolerance test and were 
 randomly assigned
34 allocated to and given placebo
 32 analysed
    2 discontinued for reasons 
        unrelated to study and excluded 
        from analysis (dropped out early 
        before any endpoints)
31 allocated to and given allopurinol
 28 analysed
         3 discontinued for reasons 
             unrelated to study and excluded 
             from analysis (dropped out early 
             before any endpoint)
Second treatment
period
28 allocated to and given placebo
 28 analysed
32 allocated to and given allopurinol
 32 analysed
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p<0·05, but the reported above mean improvement 
varied greatly from one study to another such that we 
decided prospectively to increase our numbers and 
overall recruit 60 individuals who completed the study.
This study is registered as an International Standard 
Randomised Controlled Trial, number ISRCTN 82040078.
Role of funding source
The funder had no other role in the trial whatsoever, 
except for supplying ﬁ nance and peer reviewing the 
original grant application. AN had full access to all the 
data in the study, and takes responsibility for the integrity 
of the data and the accuracy of the data analysis. The 
corresponding author had the ﬁ nal responsibilty to 
submit this report for publication.
Results
Figure 1 shows the trial proﬁ le; and table 1 shows the 
baseline characteristics of the participants. Patients were 
recruited from January, 2007,  to July, 2008, with follow-up 
during the 3 months thereafter. Five withdrew before 
completion of the study. Of the remaining 60 patients, 
28 began with allopurinol and 32 with placebo. The patients 
who withdrew were all excluded from analysis because 
none of them completed their ﬁ rst course of treatment, 
and they only had baseline ETT—ie, we did a completed 
case analysis rather than an intention-to-treat analysis 
because there were very few dropouts and their reasons for 
dropping out were unrelated to baseline values or to their 
response. Noteworthy is that no adverse eﬀ ects of treatment 
were reported.
Routine haematology (full blood count) and biochemistry 
(urea, electrolytes, liver function tests) showed that only 
alanine transaminase activity increased slightly in patients 
given allopurinol (from baseline mean 73 U/L [SD 18] to 
76 U/L [19]). Allopurinol signiﬁ cantly lowered con-
centrations of serum uric acid compared with placebo 
(baseline 0·36 mmol/L [0·06]); placebo 0·36 mmol/L 
[0·08]; allopurinol 0·14 [0·05] mmol/L; paired t test 
p<0·0001). These results were kept masked from the 
investigators to maintain treatment blinding. Diﬀ erences 
in concentrations of haemoglobin, serum urea, creatinine, 
and total cholesterol were not signiﬁ cant (table 2).
Exercise tests were stopped according to the policies of 
our local National Health Service—ie, most ETTs were 
stopped because of exhaustion or limiting angina, although 
they were stopped in seven participants with ST depression 
of greater than 2 mm in association with angina. Table 3, 
ﬁ gure 2, ﬁ gure 3, and ﬁ gure 4 show that allopurinol 
signiﬁ cantly increased total exercise time, time to ST 
depression, and time to symptoms. Compared with 
baseline, 35 (58%) patients given placebo improved in their 
time to ST depression versus 51 (85%)  given allopurinol. 
More patients taking allopurinol than those taking placebo 
showed an improvement in total exercise time (47 [78%] vs 
27 [45%]), and time to chest pain (45 [75%] vs 33 [55%]). 
Treatment did not alter the reason for ending ETT. There 
was no signiﬁ cant correlation between baseline urate and 
the eﬀ ect of allopurinol on any exercise variable.
For all three main exercise variables, there was no eﬀ ect 
with time, or any carryover eﬀ ect between treatments 
(multilevel model). The p value for treatment-carryover 
eﬀ ect was 0·80 for time to ST depression, 0·91 for total 
exercise time, and 0·60 for time to chest pain. The p 
value for time eﬀ ect was 0·74 for time to ST depression, 
All (n=60) Placebo ﬁ rst 
(n=32)
Allopurinol 
ﬁ rst (n=28)
Dropouts (n=5)
Age (years; mean, SD) 64·6 (9·3) 64·0 (8·9) 65·2 (9·6) 66·6 (7·7)
Men 50 (83%) 28 (88%) 22 (79%) 3 (60%)
Women 10 (17%) 4 (13%) 6 (21%) 2 (40%)
Angina Canadian Cardiovascular Society stage16
I 9 (15%) 4 (13%) 5 (18%) 0
II 42 (70%) 23 (72%) 19 (68%) 3 (60%)
III 9 (15%) 5 (16%) 4 (14%) 2 (40%)
Number of vessels with coronary artery disease
1 10 (17%) 4 (13%) 6 (21%) 1 (20%)
2 24 (40%) 14 (44%) 10 (36%) 2 (40%)
3 26 (43%) 14 (44%) 12 (43%) 2 (40%)
Left ventricle systolic function
Normal 51 (85%) 26 (81%) 25 (89%) 4 (80%)
Mild impairment 9 (15%) 6 (19%) 3 (11%) 1 (20%)
Renal function
Normal 55 (92%) 28 (88%) 27 (96%) 4 (80%)
Mild impairment 5 (8%) 4 (13%) 1 (4%) 1 (20%)
Medical history
Hypertension 27 (45%) 13(41%) 14 (50%) 2 (40%)
Diabetes mellitus 7 (12%) 4 (13%) 3 (11%) 1 (20%)
Hypercholesterolaemia 26 (43%) 15 (47%) 11 (39%) 2 (40%)
Peripheral vascular disease 1 (2%) 1 (3%) 0 0
Cerebral ischaemic attack or 
transient ischaemic attack
4 (7%) 3 (9%) 1 (4%) 1 (20%)
Myocardial infarction 12 (20%) 7 (22%) 5 (18%) 0
Percutaneous coronary 
intervention
7 (12%) 3 (9%) 4 (14%) 0
Coronary artery bypass graft 7 (12%) 4 (13%) 3 (11%) 0
Smoking status
Current smoker 5 (8%) 4 (13%) 1 (4%) 0
Ex-smoker 31 (52%) 14 (44%) 17 (61%) 2 (40%)
Non-smoker 24 (40%) 14 (44%) 10 (36%) 3 (60%)
Drugs
Aspirin 60 (100%) 32 (100%) 28 (100%) 4 (80%)
β blocker 52 (87%) 27 (84%) 25 (89%) 4 (80%)
Oral nitrate 29 (48%) 16 (50%) 13 (46%) 4 (80%)
Calcium antagonists 13 (22%) 7 (22%) 6 (21%) 0
Nicorandil 13 (22%) 8 (25%) 5 (18%) 1 (20%)
Angiotensin-converting-
enzyme inhibitor
28 (47%) 17 (53%) 11 (39%) 2 (40%)
Angiotensin-receptor blocker 6 (10%) 2 (6%) 4 (14%) 1 (20%)
Statin 58 (97%) 31 (97%) 27 (96%) 3 (60%)
Data are number (%), unless otherwise indicated. Percentages might not add up to 100% because of rounding.
Table 1: Baseline characteristics of participants
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0·39 for total exercise time, and 0·25 for time to chest 
pain. For missing data for the ﬁ ve participants who 
dropped out, we reanalysed the data by inserting the 
overall mean, with little diﬀ erence to any endpoint.
Haemodynamic data were normal (table 4). The 
change from baseline in the maximum heart rate and 
rate pressure product during exercise was signiﬁ cantly 
higher with allopurinol than with placebo when 
analysed with the multilevel model (paired t test). At 
the end of the ﬁ rst stage of the Bruce protocol, the 
change in systolic blood pressure from baseline was 
signiﬁ cantly lower with allopurinol than with placebo 
(multilevel model analysis and paired t test). The 
diastolic blood pressure during exercise was 
signiﬁ cantly lower in the presence of allopurinol. A 
similar analysis for the end of the second stage of the 
Bruce protocol was not done because less than half of 
patients reached the end of stage two. The number of 
patients who completed stage two was 28 at baseline, 
21 assigned to placebo, and 36 assigned to allopurinol. 
No signiﬁ cant treatment-order eﬀ ects were noted; time 
eﬀ ects were signiﬁ cant for rate pressure product at the 
end of stage 1 (p=0·02) and for maximum diastolic 
blood pressure (p=0·002).
Allopurinol reduced concentrations of brain natriuretic 
peptide (from baseline median 84·3 pg/mL [IQR 
44·8–186·0] to 65·6 pg/mL [37·0–122·7]) compared with 
placebo (80·4 pg/mL [40·1–132·8]; p=0·045). There was 
no signiﬁ cant change in concentrations of C-reactive 
protein from baseline (1·49 mg/L [0·48–2·88]) with 
allopurinol (1·47 mg/L [0·46–2·71]) or placebo (141 mg/L 
[0·63–2·78]; p=0·757).
43 participants completed and returned their angina 
diary cards (table 5). Patients were chosen because they 
had reproducible ST depression during ETT and not 
because they were symptomatic with episodes of angina. 
Allopurinol non-signiﬁ cantly halved the median number 
of angina episodes per week.  Analysis of only the 
26 individuals who had one or more episodes per week 
showed that allopurinol reduced the number of anginal 
episodes, and use of glyceryl trinitrate (table 5).
Discussion
High-dose allopurinol signiﬁ cantly prolonged the time to 
ST depression, the total exercise time, and the time to 
angina in patients with chronic stable angina during a 
standard exercise test, suggesting that endogenous 
xanthine oxidase activity contributes somehow to 
exercise-induced myocardial ischaemia. These results 
also show that high-dose allopurinol prolongs exercise in 
stable angina pectoris.
The magnitude of the anti-ischaemic eﬀ ect with 
allopurinol seems similar to that noted with other 
antianginal drugs—eg, the absolute increase in median 
time to ST depression with allopurinol was 43 s (19% 
increase). Data reported with other antianginal drugs 
were 36 s (13%) with amlodipine,10,11 60 s (11%) with 
nitrates,12 12–47 s (4–14%) with phosphodiesterase 
inhibitors,13,14 46 s (13·5%) with ivabradine,17 and about 
50 s (15%) with atenolol and ranolazine.15
What is the mechanism of the anti-ischaemic eﬀ ect of 
allopurinol? The prolonged exercise time and increased 
rate pressure product contradict any eﬀ ect of allopurinol 
on reducing cardiac work in the way that β blockers and 
ivabradine do. Allopurinol can reduce myocardial oxygen 
consumption for a particular stroke volume.1,3,4 This eﬀ ect 
might be related to reduction in oxidative stress because 
xanthine oxidase is known to use molecular oxygen to 
produce oxidative stress, and hence blocking the enzyme 
might prevent oxygen wastage and thereby increase the 
supply of molecular oxygen in ischaemic tissue.6,18,19 
Additionally, oxidative stress could directly cause an anti-
ischaemic eﬀ ect.20 Substrates for ATP, such as AMP, are 
broken down ultimately by xanthine oxidase, and, as a 
result, inhibition of this enzyme augments high-energy 
phosphates, such as ATP, which should supply essential 
energy to tissues that are depleted of energy by ischaemia.19,21 
Therefore, allopurinol could be a pill that increases oxygen 
and energy (ATP) within ischaemic tissue.
Baseline Placebo Allopurinol
Haemoglobin (g/L) 13∙8 (1∙3) 13∙6 (1∙1) 13∙5 (1∙4)
White blood cells (×109 per L) 6·7 (1·6) 6·8 (1·6) 6·6 (1·4)
Platelets (×109 per L) 224·4 (60·3) 219·6 (58·6) 218·4 (73·1)
Sodium (mmol/L) 140·5 (2·7) 140·4 (2·6) 140·4 (2·6)
Potassium (mmol/L) 4·3 (0·3) 4·3 (0·3) 4·3 (0·3)
Urea (mmol/L) 6·4 (1·5) 6·9 (1·8) 6·5 (1·7)
Creatinine (μmol/L) 84·9 (16·1) 85·0 (17·3) 82·9 (15·9)
Estimated glomerular 
ﬁ ltration rate (mL per min)
59·6 (1·7) 59·1 (3·2) 59·4 (2·4)
Data are mean (SD).
Table 2: Haematology and biochemistry results 
Baseline Placebo Allopurinol Point estimate* 
(95% CI)
Mann-Whitney 
p value*
Total exercise time (s) 301 (251–447) 307 (232–430) 393 (280–519) 58 (45–77) 0·0003
Time to ST depression (s) 232 (182–380) 249 (200–375) 298 (211–408) 43 (31–58) 0·0002
Time to symptoms (s) 234 (189–382) 272 (200–380) 304 (222–421) 38 (17–55) 0·001
Data are median (IQR), unless otherwise indicated. *For difference between allopurinol and placebo.
Table 3: Eﬀ ect of allopurinol on total exercise time, time to ST depression, and time to symptoms
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Other mechanisms could also contribute. For example, 
allopurinol improves peripheral endothelial function,6,22–28 
which has two consequences. First, it might be matched 
by an improvement in coronary endothelial function, 
meaning that coronary microvascular ﬂ ow might 
improve.29 Second, it is matched by a reduction in 
augmentation index, which means the left ventricular 
afterload is reduced.30,31 Oﬄ  oading the heart is a common 
mechanism of action for other antianginal drugs.
Thus, the anti-ischaemic eﬀ ect of allopurinol might be 
due to its eﬀ ects on oxygen and energy from ATP, but 
this eﬀ ect could be supplemented with improved 
coronary blood ﬂ ow and reduced left ventricular afterload. 
Furthermore, the eﬀ ect of allopurinol on endothelial or 
vascular function, and its eﬀ ects on oxygen and energy 
could be interlinked since increased oxygen consumption 
seems to occur especially when xanthine oxide is 
upregulated and nitric oxide synthase is downregulated.20 
Nitric oxide synthase downregulation is a common 
situation within ischaemic tissues and also one in which 
allopurinol is liable to be particularly advantageous 
because it can favourably alter both enzymes.
By contrast, we previously reported that allopurinol had 
no eﬀ ect on exercise capacity in chronic heart failure.31 
There are several good explanations for this diﬀ erence. 
First, the cause of exercise incapacity is completely 
diﬀ erent in chronic heart failure and in coronary artery 
disease. In chronic heart failure, it is due mainly to 
dyspnoea resulting from skeletal muscle underperfusion 
and ergoreﬂ ex-induced hyperventilation, whereas in 
coronary artery disease it is due to myocardial ischaemia. 
This diﬀ erence between the two types of cardiopathies can 
also be shown by the fact that treatments that improve 
exercise capacity in heart failure (angiotensin-converting-
enzyme inhibitors, spironolactone) are very diﬀ erent from 
the treatments that have antianginal eﬀ ects in coronary 
artery disease. Second, we used a lower dose of allopurinol 
(300 mg) in the previous study, and the dose response is 
steep between this dose and the 600 mg used in patients 
in the current study.6 Third, the primary endpoint was a 
mild 6 min walking test in our previous study,31 whereas it 
was a demanding Bruce protocol in the present study. The 
choice of exercise tests was appropriate for each disease 
but it is another reason not to draw too many comparisons 
between studies of patients with chronic heart failure and 
coronary artery disease.
At what stage might allopurinol ﬁ t in the treatment of 
angina pectoris? Chronic stable angina contributes to a 
substantial reduction in the quality of life, and nearly one 
in three patients has angina at least once per week.32 
Thus, many patients still do not meet the guideline goal 
according to the American College of Cardiology and 
American Heart Association of complete absence of 
exertional angina episodes.33 Therefore, new treatments 
are needed. Allopurinol might now be regarded as a 
potential drug for angina. It has many advantages 
compared with several other available antianginal drugs. 
Allopurinol is inexpensive compared with some other 
antianginal drugs such as ranolazine and ivabradine, and 
has a favourable long-term (>40 years) safety record for 
the treatment of gout. Compared with older antianginal 
drugs (nitrates, β blockers), allopurinol is better tolerated 
because it does not reduce the blood pressure or the heart 
rate, and does not cause many side-eﬀ ects, such as 
headaches and tiredness, that occur frequently with 
nitrates and β blockers. More data are needed to compare 
and contrast the use of allopurinol with other treatment 
options in patients with angina.
Figure 2: Change in total exercise time from baseline
Data are median (IQR).
Figure 3: Change in time to ST depression from baseline 
Data are median (IQR).
Figure 4: Change in time to chest pain symptoms from baseline
Data are median (IQR).
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The treatments (nitrates, calcium antagonists, and 
angioplasty) that relieve chest pain on exertion in angina 
pectoris are usually diﬀ erent from those (statins, aspirin, 
and angiotensin-converting-enzyme inhibitors) that 
reduce future cardiovascular events and mortality. Only β 
blockers seem to improve symptoms and survival. Our 
results show that high-dose allopurinol improved 
symptom relief during exercise, which alone is a treatment 
goal in angina since it is highly relevant to everyday life in 
patients with this symptom. We assessed this goal in the 
best way possible by using an objective standardised 
degree of exercise to assess whether allopurinol prolonged 
the time to key endpoints during exercise. This method is 
a more objective way of assessment of exercise capacity 
than is the use of diary cards since patients with angina 
often reduce activity in their normal daily life to reduce 
their chest pain. Furthermore, in general, our data are in 
accord with those from a study in which allopurinol 
reduced troponin release during ST-elevation myocardial 
infarction.34 The limitations of our study are the small 
sample size (although the size of the eﬀ ect and the 
p values are impressive). In the OPT-CHF trial,35 
oxypurinol was ineﬀ ective in patients with heart failure, 
probably because the dose (81 mg allopurinol equivalent) 
used was very low compared with the dose of allopurinol 
used in our study, and because drugs that have anti-
ischaemic eﬀ ects in angina seldom alter exercise capacity 
or number of deaths in patients with heart failure.
In conclusion, on the basis of our results, allopurinol is 
a useful anti-ischaemic treatment option in patients with 
angina that has the advantage of being inexpensive, well 
tolerated and safe in the long term. The precise place of 
allopurinol in the management of angina pectoris now 
needs to be explored further, but this drug might be 
especially appealing for use in developing countries where 
coronary artery disease is rapidly increasing in frequency 
and where access to expensive drugs or invasive treatments 
(angioplasty and bypass surgery) is often restricted.
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